Galena Biopharma (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, yesterday announced that Mark J. Ahn, Ph.D., President and Chief Executive Officer will present a corporate update at the 13th Annual Needham Healthcare Conference. The presentation will take place on Tuesday, April 8, 2014 at 8:40 a.m. ET at the Westin Grand Central Hotel in New York, NY. Galena Biopharma Inc. (NASDAQ:GALE) shares after opening at $2.50 moved to $2.53 on last trade day and at the end of the day closed at $2.38. Company price to sales ratio in past twelve months was calculated as 112.22 and price to cash ratio as 5.87. Galena Biopharma Inc. (NASDAQ:GALE) showed a positive weekly performance of 0.42%.
Shares of XOMA Corp (NASDAQ:XOMA) have received an average rating of “Hold” from the ten analysts that are presently covering the company, American Banking News.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $9.00. XOMA Corp (NASDAQ:XOMA) shares fell -6.11% in last trading session and ended the day on $4.92. XOMA return on equity ratio is recorded as – and its return on assets is -152.10%. XOMA Corp (NASDAQ:XOMA) yearly performance is 41.79%.
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) loss estimates have declining on the back of better-than-expected fourth quarter 2013 results. ZIOPHARM’s fourth quarter 2013 loss per share of 7 cents was narrower than the Zacks Consensus Estimate of a loss of 14 cents and 85.4% below the year-ago loss. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) shares moved down -6.06% in last trading session and was closed at $4.34, while trading in range of $4.20 – $4.65. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) year to date (YTD) performance is 0.00%.
Arrowhead Research Corporation (NASDAQ:ARWR) announced that the first cohort of 8 patients has been fully enrolled and dosed in a Phase 2a clinical trial of ARC-520, its RNAi therapeutic for the treatment of chronic hepatitis B virus infection. Arrowhead Research Corp (NASDAQ:ARWR) weekly performance is 5.14%. On last trading day company shares ended up $17.17. Arrowhead Research Corp (NASDAQ:ARWR) distance from 50-day simple moving average (SMA50) is -10.38%. Analysts mean target price for the company is $28.75.